Literature DB >> 28549947

Family history and TOMM40 '523 interactive associations with memory in middle-aged and Alzheimer's disease cohorts.

Auriel A Willette1, Joseph L Webb2, Michael W Lutz3, Barbara B Bendlin4, Alexandra M Wennberg5, Jennifer M Oh4, Allen Roses3, Rebecca L Koscik6, Bruce P Hermann7, N Maritza Dowling8, Sanjay Asthana9, Sterling C Johnson9.   

Abstract

INTRODUCTION: Family history (FH) of Alzheimer's disease (AD) affects mitochondrial function and may modulate effects of translocase of the outer mitochondrial membrane 40 kDa (TOMM40) rs10524523 ('523) poly-T length on memory decline.
METHODS: For 912 nonapolipoprotein ε4 middle-aged adults and 365 aged adults across the AD spectrum, linear mixed models gauged FH and TOMM40 '523 interactions on memory and global cognition between baseline and up to 10 years later. A cerebrospinal fluid mitochondrial function biomarker was also assessed.
RESULTS: For FH negative participants, gene-dose preservation of memory and global cognition was seen for "very long" versus "short" carriers. For FH positive, an opposite gene-dose decline was seen for very long versus short carriers. Maternal FH was a stronger predictor in aged, but not middle-aged, participants. Similar gene-dose effects were seen for the mitochondrial biomarker aspartate aminotransferase. DISCUSSION: These results may clarify conflicting findings on TOMM40 poly-T length and AD-related decline.
Copyright © 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Aspartate aminotransferase; Global function; Memory; Mitochondrial function; TOMM40

Mesh:

Substances:

Year:  2017        PMID: 28549947      PMCID: PMC5810361          DOI: 10.1016/j.jalz.2017.03.009

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  36 in total

1.  Association between mitochondrial DNA variations and Alzheimer's disease in the ADNI cohort.

Authors:  Anita Lakatos; Olga Derbeneva; Danny Younes; David Keator; Trygve Bakken; Maria Lvova; Marty Brandon; Guia Guffanti; Dora Reglodi; Andrew Saykin; Michael Weiner; Fabio Macciardi; Nicholas Schork; Douglas C Wallace; Steven G Potkin
Journal:  Neurobiol Aging       Date:  2010-06-11       Impact factor: 4.673

2.  Increased aspartate aminotransferase activity in cerebrospinal fluid and Alzheimer's disease.

Authors:  T Tapiola; M Lehtovirta; T Pirttilä; I Alafuzoff; P Riekkinen; H Soininen
Journal:  Lancet       Date:  1998-07-25       Impact factor: 79.321

Review 3.  What's wrong with Bonferroni adjustments.

Authors:  T V Perneger
Journal:  BMJ       Date:  1998-04-18

4.  Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.

Authors:  R C Mohs; D Knopman; R C Petersen; S H Ferris; C Ernesto; M Grundman; M Sano; L Bieliauskas; D Geldmacher; C Clark; L J Thal
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

5.  Insulin resistance predicts brain amyloid deposition in late middle-aged adults.

Authors:  Auriel A Willette; Sterling C Johnson; Alex C Birdsill; Mark A Sager; Bradley Christian; Laura D Baker; Suzanne Craft; Jennifer Oh; Eric Statz; Bruce P Hermann; Erin M Jonaitis; Rebecca L Koscik; Asenath La Rue; Sanjay Asthana; Barbara B Bendlin
Journal:  Alzheimers Dement       Date:  2014-07-17       Impact factor: 21.566

6.  On the discovery of the genetic association of Apolipoprotein E genotypes and common late-onset Alzheimer disease.

Authors:  Allen D Roses
Journal:  J Alzheimers Dis       Date:  2006       Impact factor: 4.472

7.  The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ε3/ε3 genotype.

Authors:  Sterling C Johnson; Asenath La Rue; Bruce P Hermann; Guofan Xu; Rebecca L Koscik; Erin M Jonaitis; Barbara B Bendlin; Kirk J Hogan; Allen D Roses; Ann M Saunders; Michael W Lutz; Sanjay Asthana; Robert C Green; Mark A Sager
Journal:  Alzheimers Dement       Date:  2011-07       Impact factor: 21.566

8.  Amino acids and transaminases activity in ventricular CSF and in brain of normal and Alzheimer patients.

Authors:  Antimo D'Aniello; George Fisher; Nicola Migliaccio; Giuseppe Cammisa; Enrico D'Aniello; Patrizia Spinelli
Journal:  Neurosci Lett       Date:  2005-11-04       Impact factor: 3.046

9.  Longitudinal modeling of cognitive aging and the TOMM40 effect.

Authors:  Richard J Caselli; Amylou C Dueck; Matthew J Huentelman; Michael W Lutz; Ann M Saunders; Eric M Reiman; Allen D Roses
Journal:  Alzheimers Dement       Date:  2012-11       Impact factor: 21.566

10.  Genetic contributions to variation in general cognitive function: a meta-analysis of genome-wide association studies in the CHARGE consortium (N=53949).

Authors:  G Davies; N Armstrong; J C Bis; J Bressler; V Chouraki; S Giddaluru; E Hofer; C A Ibrahim-Verbaas; M Kirin; J Lahti; S J van der Lee; S Le Hellard; T Liu; R E Marioni; C Oldmeadow; I Postmus; A V Smith; J A Smith; A Thalamuthu; R Thomson; V Vitart; J Wang; L Yu; L Zgaga; W Zhao; R Boxall; S E Harris; W D Hill; D C Liewald; M Luciano; H Adams; D Ames; N Amin; P Amouyel; A A Assareh; R Au; J T Becker; A Beiser; C Berr; L Bertram; E Boerwinkle; B M Buckley; H Campbell; J Corley; P L De Jager; C Dufouil; J G Eriksson; T Espeseth; J D Faul; I Ford; R F Gottesman; M E Griswold; V Gudnason; T B Harris; G Heiss; A Hofman; E G Holliday; J Huffman; S L R Kardia; N Kochan; D S Knopman; J B Kwok; J-C Lambert; T Lee; G Li; S-C Li; M Loitfelder; O L Lopez; A J Lundervold; A Lundqvist; K A Mather; S S Mirza; L Nyberg; B A Oostra; A Palotie; G Papenberg; A Pattie; K Petrovic; O Polasek; B M Psaty; P Redmond; S Reppermund; J I Rotter; H Schmidt; M Schuur; P W Schofield; R J Scott; V M Steen; D J Stott; J C van Swieten; K D Taylor; J Trollor; S Trompet; A G Uitterlinden; G Weinstein; E Widen; B G Windham; J W Jukema; A F Wright; M J Wright; Q Yang; H Amieva; J R Attia; D A Bennett; H Brodaty; A J M de Craen; C Hayward; M A Ikram; U Lindenberger; L-G Nilsson; D J Porteous; K Räikkönen; I Reinvang; I Rudan; P S Sachdev; R Schmidt; P R Schofield; V Srikanth; J M Starr; S T Turner; D R Weir; J F Wilson; C van Duijn; L Launer; A L Fitzpatrick; S Seshadri; T H Mosley; I J Deary
Journal:  Mol Psychiatry       Date:  2015-02-03       Impact factor: 15.992

View more
  6 in total

Review 1.  The effects of the TOMM40 poly-T alleles on Alzheimer's disease phenotypes.

Authors:  Ornit Chiba-Falek; William K Gottschalk; Michael W Lutz
Journal:  Alzheimers Dement       Date:  2018-03-07       Impact factor: 21.566

2.  TOMM40-APOE haplotypes are associated with cognitive decline in non-demented Blacks.

Authors:  Kacie D Deters; Elizabeth C Mormino; Lei Yu; Michael W Lutz; David A Bennett; Lisa L Barnes
Journal:  Alzheimers Dement       Date:  2021-02-13       Impact factor: 21.566

3.  Therapeutic considerations for APOE and TOMM40 in Alzheimers disease: A tribute to Allen Roses MD.

Authors:  Marwan Noel Sabbagh; Evans Pope; Laura Cordes; Jiong Shi; Boris DeCourt
Journal:  Expert Opin Investig Drugs       Date:  2020-12-02       Impact factor: 6.498

4.  Letter.

Authors:  Ara S Khachaturian
Journal:  Alzheimers Dement (Amst)       Date:  2017-11-21

5.  Biothiols and oxidative stress markers and polymorphisms of TOMM40 and APOC1 genes in Alzheimer's disease patients.

Authors:  Michal Prendecki; Jolanta Florczak-Wyspianska; Marta Kowalska; Jan Ilkowski; Teresa Grzelak; Katarzyna Bialas; Malgorzata Wiszniewska; Wojciech Kozubski; Jolanta Dorszewska
Journal:  Oncotarget       Date:  2018-10-16

6.  Genome-wide association study of hippocampal atrophy rate in non-demented elders.

Authors:  Yu Guo; Wei Xu; Jie-Qiong Li; Ya-Nan Ou; Xue-Ning Shen; Yu-Yuan Huang; Qiang Dong; Lan Tan; Jin-Tai Yu
Journal:  Aging (Albany NY)       Date:  2019-11-23       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.